Bicara Therapeutics: HC Wainwright Downgrades to Buy, PT $41 from $44.

Bicara Therapeutics: HC Wainwright Downgrades to Buy, PT $41 from $44.

Bicara Therapeutics (BCRT) has received a mixed signal from HC Wainwright & Co. The firm has downgraded its rating for Bicara Therapeutics from "Buy" to "Buy" while revising the price target from $44.00 to $41.00. The downgrade and adjustment were announced on May 16, 2025, by Robert Burns, an analyst at HC Wainwright & Co.

The price target reduction reflects a slight tempering of optimism regarding Bicara Therapeutics' growth trajectory. Despite the downgrade, the "Buy" rating indicates that HC Wainwright & Co. remains bullish on the company's prospects. Investors are advised to consider this information when evaluating their investment decisions.

Wall Street analysts have forecasted varying price targets for Bicara Therapeutics Inc (BCRT). The average target price, based on the consensus of seven analysts, is $39.14, with a high estimate of $42.00 and a low estimate of $33.00. This average target price implies an upside of 84.42% from the current price of $19.89.

The consensus recommendation from eight brokerage firms is currently 1.6, indicating an "Outperform" status. This rating scale ranges from 1 to 5, where 1 signifies a "Strong Buy" and 5 denotes a "Sell."

Investors should closely monitor Bicara Therapeutics' performance and any updates from HC Wainwright & Co. to make informed decisions.

References:
[1] https://www.gurufocus.com/news/2866140/enliven-therapeutics-elvn-target-price-raised-by-hc-wainwright-co-elvn-stock-news